AU711736B2 - Diphenyl heterocycles as potassium channel modulators - Google Patents

Diphenyl heterocycles as potassium channel modulators Download PDF

Info

Publication number
AU711736B2
AU711736B2 AU40679/97A AU4067997A AU711736B2 AU 711736 B2 AU711736 B2 AU 711736B2 AU 40679/97 A AU40679/97 A AU 40679/97A AU 4067997 A AU4067997 A AU 4067997A AU 711736 B2 AU711736 B2 AU 711736B2
Authority
AU
Australia
Prior art keywords
chloro
phenyl
oxadiazol
methyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU40679/97A
Other languages
English (en)
Other versions
AU4067997A (en
Inventor
Valentin K. Gribkoff
Piyasena Hewawasam
Scott W. Martin
Nicholas A. Meanwell
Jeffrey L. Romine
John E. Starrett Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU4067997A publication Critical patent/AU4067997A/en
Application granted granted Critical
Publication of AU711736B2 publication Critical patent/AU711736B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU40679/97A 1996-07-31 1997-07-30 Diphenyl heterocycles as potassium channel modulators Ceased AU711736B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2298396P 1996-07-31 1996-07-31
US60/022983 1996-07-31
PCT/US1997/014352 WO1998004135A1 (en) 1996-07-31 1997-07-30 Diphenyl heterocycles as potassium channel modulators

Publications (2)

Publication Number Publication Date
AU4067997A AU4067997A (en) 1998-02-20
AU711736B2 true AU711736B2 (en) 1999-10-21

Family

ID=21812455

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40679/97A Ceased AU711736B2 (en) 1996-07-31 1997-07-30 Diphenyl heterocycles as potassium channel modulators

Country Status (18)

Country Link
US (3) US5869509A (enExample)
EP (1) EP0915856A4 (enExample)
JP (1) JP2000516925A (enExample)
KR (1) KR20000029735A (enExample)
CN (1) CN1116287C (enExample)
AR (1) AR008110A1 (enExample)
AU (1) AU711736B2 (enExample)
BR (1) BR9710793A (enExample)
CZ (1) CZ32199A3 (enExample)
HU (1) HUP0000063A3 (enExample)
IL (1) IL128308A (enExample)
NO (1) NO990428L (enExample)
NZ (1) NZ334403A (enExample)
PL (1) PL331385A1 (enExample)
RU (1) RU2175319C2 (enExample)
TW (1) TW467902B (enExample)
WO (1) WO1998004135A1 (enExample)
ZA (1) ZA976554B (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
JP2002501926A (ja) * 1998-01-29 2002-01-22 ブリストル−マイヤーズ スクイブ カンパニー ジアリール１、３、４−オキサジアゾロンのホスフェート誘導体
EP1056730A4 (en) * 1998-01-29 2003-01-02 Bristol Myers Squibb Co Diaryl-1,3,4-oxadiazolone benzoate
ID26909A (id) * 1998-01-29 2001-02-15 Bristol Myers Squibb Co Turunan-turunan 1,3,4-oksadiazolon
JP2003525199A (ja) * 1998-01-29 2003-08-26 ブリストル−マイヤーズ スクイブ カンパニー ジアリール１，３，４−オキサジアゾロンアミノ酸誘導体
DE19816882A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
SE9802937D0 (sv) * 1998-09-01 1998-09-01 Astra Pharma Prod Novel compounds
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
US6632836B1 (en) 1998-10-30 2003-10-14 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
PL349097A1 (en) * 1999-01-29 2002-07-01 Bristol Myers Squibb Co Carbamate derivatives of diaryl 1,3,4-oxadiazolone
US6297241B1 (en) 1999-01-29 2001-10-02 Bristol-Myers Squibb Company Carbamate derivatives of diaryl 1,3,4-oxadiazolone
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US7018979B1 (en) 2000-01-26 2006-03-28 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
US20050153940A1 (en) * 2000-01-26 2005-07-14 Cedars-Sinai Medical Center Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
GB2361003A (en) * 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
JP2004511457A (ja) * 2000-10-13 2004-04-15 ブリストル−マイヤーズ　スクイブ　カンパニー 高い細胞内カルシウム濃度の条件下で機能する選択的マキシ−ｋカリウムチャネル・オープナー、その方法および用途
DE10056344A1 (de) * 2000-11-14 2002-05-16 Degussa n-Propylethoxysiloxane, Verfahren zu deren Herstellung und deren Verwendung
DE10058461A1 (de) * 2000-11-24 2002-09-19 Bayer Ag Substituierte Cyclohexanderivate und ihre Verwendung
US6855829B2 (en) 2001-02-20 2005-02-15 Bristol-Myers Squibb Company 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease
WO2002072090A1 (en) * 2001-03-12 2002-09-19 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
WO2002083111A2 (en) * 2001-04-16 2002-10-24 Tanabe Seiyaku Co., Ltd. Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence
US7022480B1 (en) 2001-10-11 2006-04-04 The Regents Of The University Of California Exons of the hSKCa3/KCNN3 gene
US7211561B2 (en) * 2001-10-12 2007-05-01 Cedars-Sinai Medical Center Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
US6613786B2 (en) 2001-11-02 2003-09-02 Bristol-Myers Squibb Company Thiophenyl triazol-3-one derivatives as smooth muscle relaxants
US7846671B2 (en) * 2002-01-28 2010-12-07 Bristol-Myers Squibb Company Methods of screening for agents that modulate the interaction of RGS and Gαq and urinary incontinence
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
TWI271402B (en) * 2002-10-15 2007-01-21 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
CN1826111A (zh) * 2003-04-10 2006-08-30 阿文尼尔药品公司 用于治疗变应性和过增生性疾病的咪唑衍生物
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
US20050256179A1 (en) * 2003-08-08 2005-11-17 Sircar Jagadish C Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
AU2005230867A1 (en) * 2004-03-26 2005-10-20 Amphora Discovery Corporation Certain triazole-based compounds, compositions, and uses thereof
CA2561718A1 (en) * 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
CN1993332B (zh) 2004-07-27 2011-04-06 弗·哈夫曼-拉罗切有限公司 作为非核苷逆转录酶抑制剂的苄基三唑酮化合物
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
CA2583177A1 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
ES2594874T3 (es) 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
US20080188480A1 (en) * 2005-02-22 2008-08-07 Cedars-Sinai Medical Center Use of Sildenafil, Vardenafil and Other 5-Phosphodiesterase Inhibitors to Enhance Permeability of the Abnormal Blood-Brain Barrier
EP1934185A1 (en) 2005-08-12 2008-06-25 Synta Pharmaceuticals Corporation Pyrazole compounds that modulate hsp90 activity
CA2618724A1 (en) 2005-08-18 2007-02-22 Synta Pharmaceuticals Corp. Imidazole compounds that modulate hsp90 activity
EP1928846B1 (en) * 2005-08-18 2014-06-04 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102006024024A1 (de) * 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
EP2032545A2 (en) * 2006-05-25 2009-03-11 Synta Pharmaceuticals Corporation Compounds that modulate hsp90 activity and methods for identifying same
AU2007267859B2 (en) 2006-05-25 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
WO2007139968A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
TW200804313A (en) 2006-05-25 2008-01-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
WO2008087177A1 (en) * 2007-01-18 2008-07-24 Neurosearch A/S Novel semicarbazide and carbonylhydrazide derivatives useful as potassium channel modulators
AU2008233929A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
US20100137381A1 (en) * 2007-05-03 2010-06-03 Neurosearch A/S Acetamide derivatives as potassium channel modulators
EP2280948A1 (en) 2008-04-09 2011-02-09 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers.
US20090281089A1 (en) * 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
PE20091953A1 (es) * 2008-05-08 2010-01-09 Du Pont Azoles sustituidos como fungicidas
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
JP2014532712A (ja) 2011-11-02 2014-12-08 シンタ ファーマシューティカルズ コーポレーション トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
AU2012339679A1 (en) 2011-11-14 2014-06-12 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with BRAF inhibitors
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
AU2013363398B2 (en) 2012-12-20 2017-06-01 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
MX2016002795A (es) 2013-09-06 2016-05-26 Inception 2 Inc Compuestos de triazolona y usos de los mismos.
US10681909B2 (en) 2014-08-29 2020-06-16 Fmc Corporation Herbicidal triazoles
CN104710379B (zh) * 2015-03-09 2017-01-18 华南理工大学 一种bms‑191011的合成方法
WO2020086149A1 (en) * 2018-10-26 2020-04-30 University Of South Florida Drug for treating tinnitus
AU2020363366A1 (en) * 2019-10-07 2022-04-21 D.E. Shaw Research, Llc Arylmethylene aromatic compounds as KV1.3 potassium shaker channel blockers
MX2022004127A (es) * 2019-10-07 2022-06-14 De Shaw Res Llc Compuestos heterociclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
CN115504940A (zh) * 2021-06-23 2022-12-23 中国科学院上海药物研究所 一种酰胺类化合物、其制备方法和制药用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545646B1 (de) * 1965-12-15 1969-09-18 Boehringer Sohn Ingelheim 1,3-Dimethyl-4-(2',4'-dichlorphenyl)-1,2,4-triazolon-(5) und Verfahren zu dessen Herstellung
CH583213A5 (enExample) * 1973-05-21 1976-12-31 Ciba Geigy Ag
DE2940709A1 (de) * 1979-10-08 1981-04-16 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von in 1-stellung substituierten imidazolen
US5436252A (en) * 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
CA2014537A1 (en) * 1989-04-26 1990-10-26 Yoshio Hayashi 4-imidazoline derivatives
US4966909A (en) * 1989-12-20 1990-10-30 Merrell Dow Pharmaceuticals 4-benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and their use as anticonvulsants
US5331002A (en) * 1990-04-19 1994-07-19 Merrell Dow Pharmaceuticals Inc. 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers
DE4015535A1 (de) * 1990-05-15 1991-11-21 Basf Ag Verfahren zur herstellung von n-substituierten imidazolen
IL99372A0 (en) * 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
IT1251488B (it) * 1991-09-17 1995-05-15 Mini Ricerca Scient Tecnolog Ossa(tia)diazol- e triazol-oni(tioni) ad attivita' acaricida ed insetticida
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DK28893D0 (da) * 1993-03-15 1993-03-15 Neurosearch As Benzimidazole derivater, deres fremstilling og anvendelse
US5612363A (en) * 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
ATE181328T1 (de) * 1995-11-09 1999-07-15 Synthelabo 5-(phenyl)-3-(4-piperidinyl)-1,3,4-oxadiazol- 2(3h)-on-derivate verwendbar als 5-ht4- oder h3- rezeptorliganden
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators

Also Published As

Publication number Publication date
PL331385A1 (en) 1999-07-05
IL128308A0 (en) 1999-11-30
NO990428D0 (no) 1999-01-29
US6271249B1 (en) 2001-08-07
BR9710793A (pt) 1999-08-17
JP2000516925A (ja) 2000-12-19
HUP0000063A2 (hu) 2001-01-29
CN1226803A (zh) 1999-08-25
KR20000029735A (ko) 2000-05-25
EP0915856A4 (en) 2006-04-12
AR008110A1 (es) 1999-12-09
WO1998004135A1 (en) 1998-02-05
US5869509A (en) 1999-02-09
CN1116287C (zh) 2003-07-30
ZA976554B (en) 1999-01-25
EP0915856A1 (en) 1999-05-19
CZ32199A3 (cs) 1999-06-16
NO990428L (no) 1999-01-29
NZ334403A (en) 2000-09-29
IL128308A (en) 2004-09-27
RU2175319C2 (ru) 2001-10-27
US6077861A (en) 2000-06-20
HUP0000063A3 (en) 2001-04-28
AU4067997A (en) 1998-02-20
TW467902B (en) 2001-12-11

Similar Documents

Publication Publication Date Title
AU711736B2 (en) Diphenyl heterocycles as potassium channel modulators
US7304062B2 (en) Peroxisome proliferator activated receptor alpha agonists
FI93954B (fi) Menetelmä lääkeaineina käyttökelpoisten 3,5-di-tert-butyyli-4-hydroksifenyylisubstituoitujen 1,2,4- ja 1,3,4-tiadiatsolien sekä oksadiatsolien ja triatsolien valmistamiseksi
AU735704B2 (en) Derivatives of 1,3,4-oxadiazolone
JP2002501926A (ja) ジアリール１、３、４−オキサジアゾロンのホスフェート誘導体
AU736712B2 (en) Benzoate derivatives of diaryl 1,3,4-oxadiazolone
AU740324B2 (en) New triazoles as therapeutic agents for fungal infections
CA1334201C (en) Cardiotonic alkanoyl and aroyl oxazolones
US5856350A (en) 3-phenyl-1,4-dialkyl-1,2,4-triazolium salts and their use as antidepressants
MXPA99000964A (en) Diphenyl heterocycles as potassium channel modulators
HK1022247A (en) Diphenyl heterocycles as potassium channel modulators
JPH04334373A (ja) 脊髄損傷による反射異常亢進の処置用３−アリール−５−アルキルチオ−４ｈ−１，２，４−トリアゾール類
JP2003525199A (ja) ジアリール１，３，４−オキサジアゾロンアミノ酸誘導体
JP2002535402A (ja) ジアリール１，３，４−オキサジアゾロンカーバメート誘導体